Clinical trials: CHC
Hepatitis C, Chronic
APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin
This multi-center, observational study will examine the clinical use and outcomes of pegylated interferon (PEG-IFN) alfa-2a and ribavirin combination (PEGASYS RBV) in participants with chronic hepatitis C (CHC).
- Trial name
- NCT02850289
- Testing
- Pegylated interferon (PEG-INF) alfa-2a, Ribavirin
- Where
- 46 sites in Canada
- Volunteers
- 385 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C (CHC)
Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation
This study seeks to assess the effectiveness of Glecaprevir plus Pibrentasvir in participants with chronic hepatitis C in a real-life setting across clinical practice populations in the Russian Federation.
- Trial name
- EVEREST (NCT03868163)
- Where
- 9 sites in Russia
- Volunteers
- 161 people
- Sponsor
- AbbVie
Hepatitis C, Chronic
A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6
This multicenter, open-label, uncontrolled study will evaluate the efficacy and safety of increasing the dose of peginterferon alfa-2a (Pegasys) in participants with Genotype 1/4/5/6 CHC and an early non-response to a standard…
- Trial name
- NCT02791256
- Testing
- Ribavirin, peginterferon alfa-2a
- Where
- 21 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects
GSK2878175 is a site IV NS5B non-nucleoside inhibitor (NNI) being developed for the treatment of chronic HCV infection. This study represents the first administration of GSK2878175 in humans to define safety, tolerability, and…
- Trial name
- NCT01879462
- Testing
- GSK2878175
- Where
- Australia
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy
This prospective, multi-center, observational study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) plus Copegus (ribavirin) in participants with previously untreated chronic hepatitis C, genotype 2, 3, 1…
- Trial name
- PEGHOPE (NCT01416610)
- Where
- 10 sites in Austria
- Volunteers
- 88 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic, Hepatitis C
Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)
The objective of the study is to evaluate the rates of Hepatitis C virus (HCV) eradication and relapse in participants treated with PegIntron and Rebetol in clinical practice in Greece.
- Trial name
- NCT00724464
- Testing
- PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b), Rebetol (ribavirin)
- Volunteers
- 332 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults
The primary objective of the study is to determine the number of adverse events (AEs) reported by chronic hepatitis C (CHC) patients receiving at least 1 dose of daclatasvir (DCV) and asunaprevir (ASV) at the 2 sentinel sites and…
- Trial name
- NCT03208322
- Testing
- Non-Interventional
- Where
- 2 sites in Mexico
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).
The effects of treatment with different doses of PEGASYS in combination with different doses of ribavirin will be evaluated in patients with CHC genotype 1 who have a high viral titer, body weight greater than 85kg (187lbs) and…
- Trial name
- NCT00077649
- Testing
- ribavirin [Copegus], peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients
This is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa 2b (alb-IFN)in combination with ribavirin compared with peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination…
- Trial name
- NCT00402428
- Testing
- albumin interferon alfa-2b, peginterferon alfa-2a, Ribavirin
- Where
- 165 sites in United States, Australia and 13 more
- Volunteers
- 1,331 people
- Sponsor
- Human Genome Sciences Inc.
Hepatitis C, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin
This study will evaluate the efficacy, safety and tolerability of PEGASYS plus ribavirin in patients with CHC who could not tolerate or were not responsive to 12 weeks of therapy with PEG-Intron plus ribavirin.
- Trial name
- NCT00087568
- Testing
- Ribavirin, peginterferon alfa-2a [Pegasys]
- Where
- 25 sites in United States
- Volunteers
- 57 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)
This study will compare the efficacy and safety of 2 different treatment durations of peginterferon alfa-2a (Pegasys) plus ribavirin in patients with CHC.
- Trial name
- NCT02641379
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 21 sites in Austria
- Volunteers
- 737 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)
Study is a non-interventional, prospective, multicenter post marketing surveillance study to determine the safety of daclatasvir based therapy
- Trial name
- NCT03500562
- Where
- 2 sites in China
- Volunteers
- 3 people
- Sponsor
- Bristol-Myers Squibb